| Species |
Mouse |
| Protein Construction |
KLK7 (Gln22-Arg249)
Accession # Q91VE3 |
Poly-His |
| N-term |
C-term |
|
| Purity |
> 90% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
| Expression System |
CHO |
| Apparent Molecular Weight |
24.0-28.6 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
Kallikrein-related peptidase 7 (KLK7) is a serine protease and was initially purified from the epidermis and characterised as stratum corneum chymotryptic enzyme (SCCE). It was later identified as the seventh member of the human kallikrein family. KLK7 is secreted as an inactive zymogen in the stratum granulosum layer of the epidermis and may be activated by KLK5 or matriptase. Once active, KLK7 is able to cleave desmocollin and corneodesmosin, indicating a role for KLK7 in maintaining skin homeostasis. |
| Synonyms |
Serine protease 6; Prss6; Scce; Thymopsin |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
